Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zunveyl®

Phase 3

AAlpha Cognition, Inc

Zunveyl® is one of 43 therapeutic programs targeting Alzheimer disease. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

42

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alzheimer DiseaseRecruiting

Alzheimer DiseasePhase 3

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Leqembi

Dayvigo

Estrace

Aleve

Jazz Pharmaceuticals

Cialis

Avelox

Epidiolex

Jazz Pharmaceuticals

Rifadin

Victoza

Avandia

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Alzheimer Disease

NCT07633470

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

Recruiting·AAlpha Cognition, Inc·Approved·NCT07633470·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zunveyl®. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Zunveyl®. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alpha Cognition, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAlpha Cognition, Inc

Related News